Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

AstraZeneca, Alexion's mysathenia gravis treatment enters crowded market

EndpointsView source article

Part of story

FDA approves injectable nanobody gefurulimab for myasthenia gravis

The FDA granted approval to gefurulimab, a nanobody targeting the complement protein C5, for the treatment of myasthenia gravis, joining other approved C5 inhibitors in the indication.

Nov 13, 2026·2 sourcesNeurological disordersEuropean UnionClinical trialsAutoimmune disease treatmentsRandomized controlled trialRisk evaluation & mitigation (REMS)FDA drug approvalDrug safetyDrug Policy, Pricing & Approval
FDA approves injectable nanobody gefurulimab for myasthenia gravis
00

Other sources for this story

MedPage Today

Injectable Nanobody Wins FDA Approval for Myasthenia Gravis